Larch

Other Names

Abies larixAlpine LarchArabinogalactanArabogalactanCommon LarchEastern LarchEuropean LarchGalactoarabinanGalactoarabininGomme de MélèzeHackmatackJapanese LarchL-arabino-D-galactanLarch ArabinogalactanLarch GumLarch Wood SugarLärcheLariceLarixLarix caducifoliaLarix dahuricaLarix deciduaLarix eurolepisLarix europaeaLarix gmeliniiLarix kaempferiLarix laricinaLarix larixLarix leptolepisLarix lyalliiLarix occidentalisLarix polonicaLarix sibiricaListvenitsaMélèzeMélèze d'EuropeMélèze occidentalMongolian LarchMongolian LarchwoodMontana LarchMountain LarchOregon LarchPinus LarixSiberian LarchStractanSubalpine LarchTamarackWestern LarchWestern Larch ArabinogalactanWestern TamarackWood GumWood Sugar

Synopsis

Larch (Larix spp.) and Larch Arabinogalactan: A Comprehensive Reference

1. Identity and Natural Sources

Botanical Names and Taxonomy

The term "larch" in the dietary supplement context refers to trees of the genus Larix, family Pinaceae, which also includes spruce, fir, hemlock, pine, and cedar. The Larix (larch) genus belongs to the Pinaceae (pine) family. The genus is distributed across the Northern Hemisphere and comprises several commercially and medicinally relevant species. The recognized scientific names include Larix dahurica L., Larix decidua Mill., Larix eurolepis Gord., Larix europaea, Larix gmelinii, Larix kaempferi, Larix laricina Koch., Larix leptolepis (Sieb. et Zucc.) Gord., Larix occidentalis Nutt., and Larix sibirica Ledeb.

Larix occidentalis, the Western Larch, is one of about ten species of larch trees and is considered the best source of larch arabinogalactan. The Western Larch is unique among pines in that it loses its needles in the fall. It is also known by the names Mountain Larch or Western Tamarack and is native to the Pacific and Inland Northwest United States as well as parts of British Columbia, Canada. The Eastern Larch (Larix laricina), also called tamarack or American larch, is a second major North American source. European larch (L. decidua) is cultivated in central Europe. The Dahurian larch tree (L. gmelinii/L. dahurica) is found in central Siberia and as far east as Kamchatka, Russia.

Larch trees are notable among conifers for being deciduous. Their classification places them within the order Pinales, and their deciduous coniferous nature makes them an evolutionary outlier, shedding their needles annually, unlike most evergreen conifers. Larix occidentalis trees may live to be more than 500 years old.

Primary Active Constituent: Arabinogalactan

The primary bioactive compound extracted from larch for supplement use is arabinogalactan (abbreviated AG or LA). Larch arabinogalactan (LA) is a polysaccharide powder derived from the wood of the larch tree (Larix species) and comprised of approximately 98 percent arabinogalactan. The major commercial sources of this long, densely branched, high-molecular-weight polysaccharide are North American larch trees.

It is composed of galactose and arabinose molecules in a 6:1 ratio, with a small amount of glucuronic acid. Larch arabinogalactan is approximately 98% arabinogalactan, having a galactan backbone that features β(1,3) linkages and galactose β(1,6) and arabinose β(1,6 and 1,3) sugar side chains. Arabinogalactans are long, densely branched polysaccharides of varying molecular weights (10,000–120,000). Lower molecular weight polysaccharides typically exhibit an anti-inflammatory, anti-complement, anti-allergy effect, while those of higher weights stimulate natural killer (NK) cell cytotoxicity and reticuloendothelial cells. In the case of larch arabinogalactan, molecular weights of the two major fractions are 16,000 and 100,000, perhaps accounting for its wide range of therapeutic properties.

Additional Phytochemical Constituents

Beyond arabinogalactan, larch wood and bark contain additional phytochemically significant compounds. Larch bark is a valuable source of antioxidant compounds like flavonoids and B-type procyanidins (PACs). A particularly notable secondary compound found in larch species — especially Larix gmelinii — is dihydroquercetin (also known as taxifolin), a flavonoid. Dihydroquercetin, belonging to the flavonoid class of compounds and also known as taxifolin, is associated with many health beneficial effects such as antioxidant activity, ameliorating cerebral ischemia-reperfusion injury, and modulating hepatic lipoprotein synthesis and secretion. Larch wood has been reported to contain cellulose (approximately 52.4%), lignin (approximately 28.2%), arabinogalactan (approximately 22.3% by water extraction), and dihydroquercetin (approximately 6.3% by ethanol extraction).

Common Commercial Forms and Preparations

Pharmaceutical-grade larch arabinogalactan is a fine, dry, off-white powder with a slightly sweet taste and mild pine-like odour. It dissolves completely in water or juice, is low in viscosity, and is therefore easy to administer, even to children. The proprietary product ResistAid™ is a fine, dry, light brown powder with a neutral taste that dissolves quickly in water or juice. It is produced via a water extraction patented process (US 5756098; EP 86608), in accordance with Hazard Analysis and Critical Control Points (HACCP) standards and in compliance with the monograph in the Food Chemicals Codex.

In the food industry, larch arabinogalactan is used as a stabilizer, binder, and sweetener in food products. In pharmaceutical research applications, larch arabinogalactan has also been investigated as a drug-delivery vehicle, particularly for hepatic targeting, owing to its affinity for the asialoglycoprotein receptor on hepatocytes.

Beyond the isolated polysaccharide, larch bark represents a processing by-product of the wood industry and is used in traditional medicine as a diuretic, expectorant, antiseptic, and for the treatment of purulent wounds, chronic eczema, and psoriasis.

2. Traditional and Historical Use

Indigenous North American Traditions

For many nations, such as the Cree, Algonquin, and Innu, the larch was not simply a plant, but an essential partner in life — a source of materials, medicines, and knowledge. Indigenous peoples were the first to decipher the secrets of this tree. Arabinogalactan has been consumed by humans for thousands of years and is found in a variety of common vegetables as well as in medicinal herbs.

According to the Native American Ethnobotany Database, Eastern Larch (Larix laricina) was used medicinally by numerous nations: the Algonquin used an infusion of needles and bark to treat coughs, and infusions of young branches served as a laxative; the Anticosti used a decoction of bark mixed with other plants for kidney troubles; the Chippewa applied a poultice of inner bark to burns and used infusions of bark to treat anemia; the Cree mixed tamarack with other tree products to induce vomiting and boiled inner bark was applied to wounds to draw out infection; the Iroquois made decoctions of Eastern Larch as an analgesic, and to treat rheumatism, colds, and gonorrhea; and the Malecite used it as a tuberculosis remedy.

For Western Larch (Larix occidentalis), tribes of the Pacific Northwest and interior regions had distinct ethnobotanical practices. The Nlaka'pamux used a decoction of small pieces of branches and tops for cancer treatments, and made poultices out of the pitch mixed with fat for sores, cuts, and burns. The Okanagan-Colville used a decoction of plant tops to soak severe skin sores, and mixed it with Oregon grapes as a blood purifier. They also ingested an extraction of the plant to treat severe arthritis. The Paiute and the Okanagan-Colville gathered the syrup or "dark candy" from larch and used it as a confection.

The Ojibwe used the crushed needles and bark similarly to how they would use white pine. Likewise, the Potawatomi used the roots and bark from the trunk. The fresh inner bark was used for poulticing wounds and inflammation; steeped bark was consumed as a tea.

European Traditional Medicine

Larch trees were reportedly introduced to Great Britain in 1639 and have been cultivated there since the early 19th century. In European herbalism, larch bark and its extracts were valued for their immune-boosting properties and were commonly used to treat respiratory ailments, such as coughs, bronchitis, and sore throats. Folk remedies often employed larch as a gentle expectorant, helping to clear mucus and soothe irritated airways. Additionally, larch was believed to support digestive health and was sometimes used to address mild gastrointestinal discomfort. Coverage in M. Grieve's Modern Herbal notes that the bark was used as a laxative, tonic, diuretic, and alterative, and that it has widely been used for treating issues with the liver, rheumatism, jaundice, and dysentery.

3. Key Constituents and Mechanisms of Action

Arabinogalactan Structure

Larch arabinogalactan is a type II arabinogalactan — a long, densely branched polysaccharide. Larch arabinogalactan (LA-AG) consists of a β-1,3-galactan main chain and short β-1,6-galactan side chains substituted with arabinose residues. Its resistance to digestion in the upper gastrointestinal tract is fundamental to its biological activity. Arabinogalactan fulfills key prebiotic criteria by reaching the colon undigested, being selectively fermented by beneficial gut bacteria such as Bifidobacterium, and contributing to the production of health-promoting short-chain fatty acids (SCFAs).

Immunomodulatory Mechanisms

In cell and animal models, larch arabinogalactan is capable of enhancing natural killer cells and macrophages as well as the secretion of pro-inflammatory cytokines. Arabinogalactan is an immunomodulator that has been shown to activate human peripheral blood mononuclear cells (PBMCs) to release proinflammatory cytokines and stimulate NK cell activity.

Lower molecular weight polysaccharides typically exhibit an anti-inflammatory, anti-complement, and anti-allergy effect, while those of higher molecular weights stimulate natural killer (NK) cell cytotoxicity and reticuloendothelial cells. The presence of two distinct major fractions at 16,000 and 100,000 molecular weight in larch arabinogalactan means that both immune-dampening and immune-activating activities are potentially attributable to the same preparation.

Improvements of serum antigen-specific IgG and IgE response to Streptococcus pneumoniae and tetanus vaccination, suggesting a B cell-dependent mechanism, have been reported in vaccination studies with larch arabinogalactan, while the absence of response following influenza vaccination suggests the involvement of a T cell-dependent mechanism.

Prebiotic and Gut Fermentation Mechanisms

The polysaccharide's β-1,3 and β-1,6 glycosidic bonds resist upper digestive tract enzymes, allowing it to reach the colon intact for prebiotic activity. Once in the colon, non-absorbed larch arabinogalactan is actively fermented by intestinal microflora and is particularly effective at increasing beneficial anaerobes such as Bifidobacteria and Lactobacillus. It is an excellent source of dietary fibre able to increase short-chain fatty acid production, primarily butyrate, via vigorous fermentation by intestinal microflora. Butyrate is essential for proper colon health as it is the preferred substrate for energy generation by colonic epithelial cells.

Larch arabinogalactan degradation by gut microbiota has been characterized by investigating changes in microbiota composition and the production of short-chain fatty acids (SCFAs), lactic acid, succinic acid, as well as volatile organic metabolites. During fermentation, pH decreases continuously, with organic acids (especially acetic acid and lactic acid) accumulating. Larch arabinogalactan was degraded by gut microbiota and beneficial metabolites were produced. Additionally, larch arabinogalactan inhibited the proliferation of certain gut microbiota (including unclassified Enterobacteriaceae and Citrobacter) and the accumulation of certain metabolites (sulfide and indole) released by gut microbiota.

Larch arabinogalactan has been shown to increase short-chain fatty acids, decrease colonic ammonia levels, increase the numbers of beneficial bacteria in the colon, as well as improve the immune response. Elevated colonic ammonia, a by-product of bacterial protein fermentation, can be detrimental to the colonic epithelium, and the ammonia-lowering effect of arabinogalactan fermentation represents a potentially protective mechanism for gut mucosal health.

Hepatic Affinity

Arabinogalactan binds to the asialoglycoprotein receptor, which is expressed predominantly on hepatocytes, making it of research interest for targeted hepatic drug delivery. Animal studies indicate that intravenous injection of purified larch arabinogalactan results in 52.5% of the dose being present in the liver and 30% in the urine 90 minutes after dosing. Hepatic clearance occurred with a half-life of 3.42 days.

4. Scientific Evidence by Area of Use

4.1 Upper Respiratory Tract Infections and Common Cold

This is the most clinically studied application of larch arabinogalactan. Recent human studies have demonstrated that dietary intervention with arabinogalactan from North American Larix species could increase resistance to infections.

Key clinical study (Riede et al., 2013): In a placebo-controlled, double-blind, randomized clinical trial, the effect of a proprietary larch arabinogalactan preparation on the incidences of common colds and its effect on cold symptoms was examined. In the full analysis set (FAS), arabinogalactan tended to decrease the incidence of common cold (p = 0.055). The number of participants affected by a cold was significantly reduced by arabinogalactan supplementation (p = 0.038). Specifically, in humans, the clinical study demonstrated that larch arabinogalactan increased the body's potential to defend against common cold infection, and decreased the incidence of cold episodes by 23%.

Limitations: The study demonstrated that larch arabinogalactan increased the body's potential to defend against common cold infection, but its mechanism of action remains to be elucidated. The three studies performed in healthy adults suggest that larch arabinogalactan might influence TNF-α secretion and modulate the proportion of immune cell populations, while other parameters such as immunoglobulin levels, NK cell levels and activity, or neutrophils activity seemed unaffected. In these clinical trials, however, the relevance of the model (healthy subjects and absence of immune challenge) and markers could be questioned.

4.2 Vaccine Adjuvant / Antibody Response Enhancement

Several randomized, double-blind, placebo-controlled clinical trials have examined larch arabinogalactan's ability to enhance antibody responses to standardized vaccine challenges.

Pneumococcal vaccine study (Udani et al., 2010 — pilot RCT, N=45): This randomized, double-blind, placebo-controlled, parallel-group pilot study included 45 healthy adults who had not previously been vaccinated against Streptococcus pneumoniae. The volunteers began taking the study product or placebo at a daily dosage of 4.5 g and continued over the entire 72-day study period. After 30 days, the subjects received the 23-valent pneumococcal vaccine. The arabinogalactan group demonstrated a statistically significant greater IgG antibody response than the placebo group in two antibody subtypes (18C and 23F) at both Day 51 (p = 0.006 and p = 0.002) and at Day 72 (p = 0.008 and p = 0.041). These same subtypes also demonstrated change scores from baseline that were significant in favor of the arabinogalactan group. Change scores from baseline and mean values were greater in the arabinogalactan group than placebo for most time points in antibody subtypes 4, 6B, 9V, and 19F, but these differences did not reach statistical significance. No differences in total white blood cell count, cytokines, or complement levels occurred between the two groups.

Tetanus and influenza vaccine study (RCT, N=75): This randomized, double-blind, placebo-controlled trial included 75 healthy adults (18–61 years old). Subjects were randomized to receive either 1.5 or 4.5 g/day of ResistAid or placebo for 60 days. At day 30, subjects were administered both tetanus and influenza vaccines. A study by the same research group compared the effectiveness of ResistAid® at a daily dose of 1.5 g to a placebo and demonstrated a significant increase in IgG antibody response to the tetanus vaccine, while no improvement was observed following the influenza vaccine.

These results taken together suggest that larch arabinogalactan can improve immunity by decreasing infections and improving immunoglobulin response following a standardized immune challenge. However, the field is limited by relatively small trial sizes and the studies have been primarily conducted in healthy volunteers.

4.3 Prebiotic and Gastrointestinal Effects

Larch arabinogalactan has been approved for use as a dietary fiber by the U.S. Food and Drug Administration (FDA). Its prebiotic designation rests on well-characterized mechanisms. Arabinogalactan fulfills key prebiotic criteria by reaching the colon undigested, being selectively fermented by beneficial gut bacteria such as Bifidobacterium, and contributing to the production of health-promoting short-chain fatty acids.

The non-absorbed fiber of arabinogalactan is easily fermented by the distal gut microflora, resulting in elevated production of short-chain fatty acids, primarily butyrate, and, to a lesser extent, propionate. Human and in vitro studies consistently support the selective fermentation profile. A key limitation in this area is that most robust mechanistic findings come from in vitro fermentation studies, while confirming in vivo clinical data in humans remain comparatively limited.

Early research shows that taking larch arabinogalactan does not lower total cholesterol, low-density lipoprotein (LDL or "bad") cholesterol, other blood fats called triglycerides, body weight, blood pressure, or sugar levels in healthy people. This indicates that the metabolic benefits hypothesized from gut fermentation have not yet been confirmed in clinical studies of healthy individuals.

4.4 Echinacea Combination / Immune Function in Healthy Adults

Kim et al., 2002 (RCT, N=48): The immunomodulating effects of two Echinacea species and larch arabinogalactan extracted from Larix occidentalis were examined in a randomized, double-blind, placebo-controlled, prospective four-week clinical trial. Forty-eight healthy female volunteers (22–51 years old) were randomly assigned to one of six groups. Volunteers in certain groups had increased production of complement properdin after four weeks of intervention. The increased complement properdin may be an indication of one aspect of immune system stimulation. Lymphocyte proliferation was significantly increased at 6 weeks compared to baseline in the arabinogalactan group, which was not the case in the control group. Other parameters including serum IgG levels, respiratory burst activity of neutrophils, NK cell number, and B cell number remained unchanged.

4.5 Colitis and Gut Inflammation (Preclinical)

Recent preclinical research has begun to probe larch arabinogalactan's effects on gut inflammation. Research findings show that larch arabinogalactan treatment was associated with anti-inflammatory activity, including production of propionate and upregulation of colonic G-protein-coupled receptor 41 (GPR41) expression. These are animal and in vitro findings, and their translation to human clinical outcomes requires further investigation.

4.6 Hepatic Drug Delivery (Research Application)

Larch arabinogalactan has been studied as a vehicle for targeted liver drug delivery. Its strong affinity for the hepatic asialoglycoprotein receptor has been leveraged in pharmacological research. Of radiolabeled arabinogalactans, 52.5% (4 mg/kg) were identified in the livers of rats receiving an intravenous (IV) injection. This line of research concerns pharmaceutical formulation rather than dietary supplement use.

5. Body Systems and Health Areas Associated with Larch

Immune system: Larch arabinogalactan seems to positively influence NK cells, macrophage activities, and pro-inflammatory cytokine production.
Gastrointestinal / microbiome: Larch arabinogalactan has been shown to support immune function, SCFA levels, and to act as a prebiotic for gut bacteria, particularly Bifidobacteria.
Respiratory tract: Historically, indigenous peoples of North America used larch extracts for their health-supporting properties, particularly as a remedy for respiratory issues and as a general tonic. Clinical evidence now supports a modest reduction in upper respiratory infections.
Hepatic system: High affinity binding to liver hepatocytes via the asialoglycoprotein receptor, though clinical supplement implications are not yet established.
Polyphenol/antioxidant activity (bark constituents): Larch bark is a valuable source of antioxidant compounds like flavonoids and B-type procyanidins, and may represent an innovative and sustainable ingredient for pharmaceutical, nutraceutical, and cosmetic purposes.

6. Dosage Forms and Dosages Reported in Studies

Larch arabinogalactan is approved by the US Food and Drug Administration (FDA) as a source of dietary fiber and for use in food products. The typical adult dose reported is 1 to 3 tablespoons per day of larch arabinogalactan powder in divided doses. The powder can be mixed with water or juice, or added to food.

Specific dosages used in clinical research trials include:

A pilot RCT in 45 healthy adults used a daily dosage of 4.5 g of ResistAid™ over the entire 72-day study period.
A 75-person RCT randomized subjects to receive either 1.5 or 4.5 g/day of ResistAid™ or placebo for 60 days.
Two of the three retrieved clinical studies explored the effect of larch arabinogalactan on TNF-α in serum following four weeks' supplementation at 1.5 g/d.
In the tolerability study, 199 healthy participants received an arabinogalactan preparation over a period of 12 weeks.
In numerous previous clinical studies in humans, no significant safety issues were observed at intakes of up to 30 g daily for up to 6 weeks.

Arabinogalactan extract (ResistAid) at 1.5 to 4.5 g/day for 60 to 72 days, beginning 30 days prior to vaccine administration, has also been specifically reported in immunological study protocols.

7. Regulatory Status

Larch arabinogalactan was approved by the Food and Drug Administration in 1965 for direct addition to food and gained Generally Recognized As Safe (GRAS) notification in 2000. The larch arabinogalactan used in the ResistAid™ product has been designated as Generally Recognized as Safe (GRAS) with the US FDA (GRAS Notice Nos. GRN000047 and GRN000084). There is a Food Chemical Codex Monograph for arabinogalactan available.

8. Safety, Tolerability, and Notable Interactions

General Safety Profile

Based on food grade status and numerous studies supporting the safety of larch arabinogalactan, it is considered to be extremely safe with minimum to no toxicity. Preclinical safety data is robust: arabinogalactan produced no adverse reactions when administered as single IV doses of 5,000 mg/kg in mice, or as repeat doses of 500 mg/kg/day for 90 days in rats.

The tolerability clinical trial by Grube et al. (2012) is the most directly applicable human safety study. In this placebo-controlled, double-blind, randomized clinical trial, 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. Safety parameters evaluated included the total number of adverse events, changes in various biochemical and laboratory parameters, and the global evaluation of tolerability by investigator and subjects. In total, 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. ResistAid™ was rated as "very good" or "good" by 98% of the subjects and for 99% of the subjects by the investigator.

Gastrointestinal Effects

As a fermentable fiber, larch arabinogalactan is possibly safe when taken in doses of 1.5–8.4 grams daily for less than 6 months. It can cause side effects such as bloating and intestinal gas (flatulence). There is insufficient reliable information to know if it is safe to use for longer than 6 months or what the side effects might be.

Autoimmune Conditions

Larch should not be used in patients with autoimmune disorders such as systemic lupus erythematosus, Crohn's disease, or rheumatoid arthritis due to its stimulating effects on the immune system. This caution reflects the theoretical risk that immune stimulation could exacerbate autoimmune disease activity, though this has not been directly observed in available clinical trials.

Tuberculosis

Larch is not recommended in patients with tuberculosis because arabinogalactans are structural components of the cell walls of mycobacterium. The concern is that supplemental arabinogalactan could theoretically interfere with immune recognition or complement antimycobacterial immune responses, though direct clinical evidence for this interaction is lacking.

Drug Interactions — Immunosuppressants

Larch arabinogalactan seems to increase the activity of the immune system. By increasing immune activity, larch arabinogalactan might decrease the effectiveness of medications that decrease the immune system. Some medications that decrease immune system activity with which a theoretical interaction could occur include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3, mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone, corticosteroids (glucocorticoids), and others.

If a patient has received an organ transplant, larch arabinogalactan should not be used until more is known.

Occupational Exposure

Occupational exposure to larch dust may cause chronic lung, eye, and skin irritation. This is distinct from oral supplemental use and applies primarily to workers in the wood-processing industry.

Pregnancy and Lactation

Clinical information regarding safety and efficacy in pregnancy and lactation is lacking. Arabinogalactan is not recommended in pregnant or breastfeeding women due to a lack of available scientific evidence.

Overall Strength of Evidence

Arabinogalactan, which is present in some larch species, has been reported to stimulate the immune system and boost antibody response to vaccines. It may be useful in treating upper respiratory infections. However, very limited clinical trials, primarily conducted in healthy individuals, support these uses. While larch arabinogalactan is often proposed as a dietary supplement for general immune support, evidence from clinical studies remains limited and inconclusive. Current evidence is most consistent for modest reduction in common cold incidence and augmented antibody responses in specific vaccine models. The prebiotic activity is mechanistically well-supported but lacks large, long-term human clinical trials. Most research involves proprietary preparations (ResistAid™, ResistAid®), limiting generalizability to other commercial products.

References

Health Conditions

Health conditions that Larch may help support.

No conditions available.

Body Systems

Body systems that Larch may help support.

No body systems available.